Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 0.49 |
| ▸ | PPARG | P37231 | 3/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15981193 | 0.87 | CYP17A1 (0.51) | CYP17A1PPARGPPARASMN1; SMN2MAPT | |
| SCHEMBL15538944 | 0.82 | SMN1; SMN2 (0.59) | CYP17A1PPARGPPARASMN1; SMN2MAPT | |
| SCHEMBL2848809 | 0.81 | PPARG (0.49) | CYP17A1PPARGPPARASMN1; SMN2MAPT | |
| SCHEMBL25977924 | 0.79 | SMN1; SMN2 (0.40) | SMN1; SMN2MAPTLMNAGLSNPC1 | |
| SCHEMBL19558427 | 0.78 | SMN1; SMN2 (0.39) | SMN1; SMN2MAPTLMNANPC1TP53 | |
| SCHEMBL3173008 | 0.78 | PPARG (0.53) | CYP17A1PPARGPPARASMN1; SMN2MAPT | |
| SCHEMBL977842 | 0.78 | PTGDR2 (0.60) | CYP17A1PPARGPPARASMN1; SMN2PTGDR2 | |
| SCHEMBL16807762 | 0.78 | CYP17A1 (0.58) | CYP17A1PPARGPPARASMN1; SMN2MAPT | |
| SCHEMBL5726965 | 0.76 | CYP17A1 (0.57) | CYP17A1PPARGPPARASMN1; SMN2MAPT | |
| SCHEMBL15709727 | 0.76 | LMNA (0.62) | CYP17A1PPARGPPARASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767292-B2 | Process for making beta 3 agonists and intermediates | MERCK SHARP & DOHME CORP. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767292-B2 | Process for making beta 3 agonists and intermediates | MERCK SHARP & DOHME CORP. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11708371-B2 | Process for making beta 3 agonists and intermediates | MERCK SHARP & DOHME CORP. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708371-B2 | Process for making beta 3 agonists and intermediates | MERCK SHARP & DOHME CORP. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11124478-B2 | Process for making beta 3 agonists and intermediates | MERCK SHARP & DOHME CORP. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210221815-A1 | Process for Making Beta 3 Agonists and Intermediates | MERCK SHARP & DOHME CORP. (US) | 2021-07-22 | — | — | US | disclosed |
| US-20200290962-A1 | Process for Making Beta 3 Agonists and Intermediates | MERCK SHARP & DOHME LLC | 2020-09-17 | — | — | US | disclosed |
| US-10577316-B2 | Process for making beta 3 agonists and intermediates | MERCK SHARP & DOHME CORP. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20200031838-A1 | Process for Making Beta 3 Agonists and Intermediates | MERCK SHARP & DOHME CORP. (US) | 2020-01-30 | — | — | US | disclosed |
| US-10435410-B2 | Process for making beta 3 agonists and intermediates | MERCK SHARP & DOHME CORPORATION (US) | 2019-10-08 | — | — | US | disclosed |
| CN-1893977-B | By EP4Medicine with agonist as active component for treating diseases related to bone loss | ONO PHARMACEUTICAL CO | 2012-12-05 | — | — | CN | disclosed |
| US-20120202773-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| US-8207223-B2 | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| CN-101921220-A | Treat the EP that contains with the bone mass loss diseases associated 4Agonist is as the pharmaceutical composition of activeconstituents | ONO PHARMACEUTICAL CO | 2010-12-22 | — | — | CN | disclosed |
| EP-2255829-A2 | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient | Ono Pharmaceutical Co., Ltd. (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-20100010222-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-7608637-B2 | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-10-27 | — | — | US | disclosed |
| CN-1893977-A | By EP4Medicine with agonist as active component for treating diseases related to bone loss | ONO PHARMACEUTICAL CO (JP) | 2007-01-10 | — | — | CN | disclosed |
| US-20050020686-A1 | Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient | ONO PHARMACEUTICAL CO. LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1417975-A1 | REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP sb 4 /sb AGONIST AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221815-A1 | Process for Making Beta 3 Agonists and Intermediates | ADRB3, ADRB2, ADRB1 | CYP17A1 80/4885PPARG 909/4885PPARA 1233/4885 |
| US-20200290962-A1 | Process for Making Beta 3 Agonists and Intermediates | ADRB3, ADRB1, ADRB2 | CYP17A1 44/4885PPARG 1736/4885PPARA 2011/4885 |
| US-11767292-B2 | Process for making beta 3 agonists and intermediates | ADRB3, ADRB1, ADRB2 | CYP17A1 44/4885PPARG 1736/4885PPARA 2011/4885 |
| US-20120202773-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT | PTGER4, PTGER1, PTGER2 | CYP17A1 2079/4885PPARG 72/4885PPARA 201/4885 |
| US-20050020686-A1 | Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient | PTGER4, PTGER1, PTGER3 | CYP17A1 1693/4885PPARG 72/4885PPARA 177/4885 |
| US-10435410-B2 | Process for making beta 3 agonists and intermediates | ADRB3, ADRB2, ADRB1 | CYP17A1 80/4885PPARG 909/4885PPARA 1233/4885 |
| US-11124478-B2 | Process for making beta 3 agonists and intermediates | ADRB3, ADRB1, ADRB2 | CYP17A1 44/4885PPARG 1736/4885PPARA 2011/4885 |
| US-10577316-B2 | Process for making beta 3 agonists and intermediates | ADRB3, ADRB1, ADRB2 | CYP17A1 44/4885PPARG 1736/4885PPARA 2011/4885 |
| US-20100010222-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT | PTGER4, PTGER1, PTGER2 | CYP17A1 2079/4885PPARG 72/4885PPARA 201/4885 |
| US-11708371-B2 | Process for making beta 3 agonists and intermediates | ADRB3, ADRB2, ADRB1 | CYP17A1 80/4885PPARG 909/4885PPARA 1233/4885 |
| US-20200031838-A1 | Process for Making Beta 3 Agonists and Intermediates | ADRB3, ADRB2, ADRB1 | CYP17A1 80/4885PPARG 909/4885PPARA 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.